Clinical Trials Logo

Lung Cancer clinical trials

View clinical trials related to Lung Cancer.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06399926 Recruiting - Lung Cancer Clinical Trials

Efficacy and Safety of Intraventricule Pemetrexed Disodium Administered Via Ommaya Reservoir

Start date: October 30, 2023
Phase:
Study type: Observational

This is a open-label, multi-center prospective observation study for the efficacy and safety of intraventricle pemetrexed disodium via ommaya reservoir in the treatment of leptomeningeal metastasis with lung cancer who have failed at least one targeted therapy. In detail: At least the treatment failure was after third-generation EGFR-TKIs in EGFR-mutated lung cancer; or at least the treatment failure was after second-generation ALK-TKIs in ALK-mutated lung cancer; or at least the treatment failure was after one-line of targeted-TKIs in ROS1-mutated non-squamous non-small lung cancer.

NCT ID: NCT06387017 Recruiting - Lung Cancer Clinical Trials

Prospective Multicenter Cohort Study to Validate Four Groups of Biomarkers for Assessing Lung Cancer Risk Among Patients With Atheromatous Cardiovascular Disease in a Screening Pathway

BIOCEPTION
Start date: April 2, 2024
Phase: N/A
Study type: Interventional

Interventional study with minimal risks and constraints, with evaluation of the incidence of lung cancers by low-dose thoracic CT scan without injection of contrast medium, of the immunological, inflammatory and metabolic blood profile and of the microbiota; systematic proposal of smoking cessation for active smokers or assistance in maintaining cessation.

NCT ID: NCT06383728 Recruiting - Lung Cancer Clinical Trials

Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma

GALAXY-02
Start date: April 1, 2024
Phase: Phase 2
Study type: Interventional

Previous trials, such as ADURA and CTONG, have demonstrated the benefits of neoadjuvant targeted therapy in patient with EGFR mutations , which can effectively reduce the extent of tumors and improve the survival outcomes. However, clinical trials of neoadjuvant targeted therapy in NSCLC have rarely enrolled patients with EGFR-mutated lung squamous cell carcinoma due to its rarity, which means that the safety and feasibility of neoadjuvant osimertinib in patients with resectable stage II-IIIB EGFR-mutated lung squamous cell carcinoma remains controversial.

NCT ID: NCT06381960 Recruiting - Lung Cancer Clinical Trials

Clinical Study on the Prevention and Treatment of Postoperative Metastasis of Lung Cancer by Fuzheng Quxie Recipe

Start date: March 1, 2023
Phase: Phase 2
Study type: Interventional

To address the clinical challenge of postoperative metastasis in stage IIA-IIIA non-small cell lung cancer with negative driver gene expression, there is a lack of effective diagnostic and therapeutic measures. Based on this, investigators propose to carry out a clinical study on the prevention and treatment of postoperative metastasis of IIA-IIIA stage lung cancer with negative driver gene expression with the formula of supporting the positive and dispelling the evil.

NCT ID: NCT06380361 Recruiting - Lung Cancer Clinical Trials

InvestigatioN of a Smart Probe for Lung lEsion Characterization Using Impedance Technology

INSPECT
Start date: April 2, 2024
Phase: N/A
Study type: Interventional

The objective of the study is to evaluate the feasibility of the BioSpy System sensor to differentiate tissues that are encountered during bronchoscopic biopsy of endobronchial tumors and peripheral lung nodules and masses.

NCT ID: NCT06376097 Recruiting - Lung Cancer Clinical Trials

Lung Cancer Screening Program Using Low-dose Tomography and Metabolomic Evaluation in a Public Service.

Start date: April 19, 2023
Phase:
Study type: Observational

Observational study that aims to evaluate the implementation of a lung cancer screening program in a smoker population included in a public heath service.

NCT ID: NCT06363123 Recruiting - Breast Cancer Clinical Trials

Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis

Start date: March 29, 2024
Phase:
Study type: Observational

The aim of this observational study is to comprehensively analyze the metabolites in plasma samples from multi-cancer patients using advanced mass spectrometry detection technology, in conjunction with metabolomics approaches. The goal is to construct a plasma metabolite database for multi-cancer patients. Simultaneously, we will delve into the exploration and validation of a series of metabolic biomarkers for early multi-cancer diagnosis. The objective is to establish a safer, more convenient, and more sensitive early screening method, thereby providing a reliable scientific foundation and critical evidence for improving the early diagnostic process for individuals at high risk of multi-cancer.

NCT ID: NCT06360822 Recruiting - Lung Cancer Clinical Trials

Increasing Equity in Lung Cancer Screening

LUCARE
Start date: December 1, 2023
Phase: N/A
Study type: Interventional

The overall objective of this mixed methods study is to: 1) Refine the Emergency Department Lung Cancer Screening (ED-LCS) intervention using qualitative interviews among key stakeholders; 2) pilot test the ED-LCS intervention evaluating the intervention efficacy, acceptability, and feasibility; and 3) provide an in-depth description of stakeholders' experiences with the ED-LCS intervention for future refinement.

NCT ID: NCT06360627 Recruiting - Lung Cancer Clinical Trials

Ultra Low Dose CT and Use of Iomeron 400 in PCD-CT

Start date: February 20, 2023
Phase: N/A
Study type: Interventional

Evaluation of ultra low dose protocols and Iomeron 400 contrast in PCD-CT

NCT ID: NCT06351085 Recruiting - Lung Cancer Clinical Trials

Enhancing Lung Cancer Screening Through Human-Centered Intervention

ELFE
Start date: November 10, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to further understand the factors involved in increasing lung cancer screening.